Glucagonoma medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Glucagonoma}} | {{Glucagonoma}} | ||
{{CMG}}{{AE}}{{PSD}} | {{CMG}}; {{AE}} {{PSD}} {{MAD}} | ||
==Overview== | ==Overview== | ||
The predominant medical therapy for primary glucagonoma is [[Somatostatin|Somatostatin analogs]] ([[octreotide]]). Metastatic tumors need [[Therapeutic embolization|'''Hepatic''' artery embolization]], [[Radiofrequency ablation]], and [[Molecularly therapy]]. | The predominant medical therapy for primary glucagonoma is [[Somatostatin|Somatostatin analogs]] ([[octreotide]]). Metastatic tumors need [[Therapeutic embolization|'''Hepatic''' artery embolization]], [[Radiofrequency ablation]], and [[Molecularly therapy]]. | ||
| Line 20: | Line 20: | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 19:22, 2 August 2017
|
Glucagonoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Glucagonoma medical therapy On the Web |
|
American Roentgen Ray Society Images of Glucagonoma medical therapy |
|
Risk calculators and risk factors for Glucagonoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2] Mohammed Abdelwahed M.D[3]
Overview
The predominant medical therapy for primary glucagonoma is Somatostatin analogs (octreotide). Metastatic tumors need Hepatic artery embolization, Radiofrequency ablation, and Molecularly therapy.
Management of primary tumor
- Somatostatin analogs (octreotide) are the treatment of choice to control symptoms.[1]
- Doxorubicin and streptozotocin have also been used successfully to selectively damage alpha cells of the pancreatic islets.
Metastasis therapy
Hepatic artery embolization
- Hepatic arterial embolization is a palliative treatment in patients with symptomatic hepatic metastases who are not candidates for surgical resection. Embolization can be performed via the infusion through an angiography catheter into hepatic arteries.
Radiofrequency ablation
- Ablation can be performed percutaneously or laparoscopically in patients with symptomatic hepatic metastases who are not candidates for surgical resection. Ablation is applicable only to smaller lesions less than 3 cm.[2]
Molecularly therapy
- Sunitinib is a radiolabeled somatostatin analog which has a role in the management of glucagonomas that are not symptomatic or have rapidly progressive metastasis.
References
- ↑ Rosenbaum A, Flourie B, Chagnon S, Blery M, Modigliani R (1989). "Octreotide (SMS 201-995) in the treatment of metastatic glucagonoma: report of one case and review of the literature". Digestion. 42 (2): 116–20. PMID 2548911.
- ↑ Gupta S, Yao JC, Ahrar K, Wallace MJ, Morello FA, Madoff DC; et al. (2003). "Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience". Cancer J. 9 (4): 261–7. PMID 12967136.